Table 7 Comparison of dosage formulations
From: Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
Formulation | Drug concentration (μg/ml) | p |
|---|---|---|
Posaconazole | ||
 Delayed-release tablet (median [IQR]) | 1.48 (0.76–2.21) | <0.01 |
 IV (median [IQR]) | 1.74 (1.47–2.56) |  |
 Oral suspension (median [IQR]) | 0.40 (0.17–0.95) |  |
Voriconazole | ||
 IV (median [IQR]) | 3.31 (1.41–5.70) | <0.01 |
 PO (median [IQR]) | 1.78 (0.84–4.00) |  |
| Â | Therapeutic drug level | Non-therapeutic drug level | OR (95% CI) | p |
|---|---|---|---|---|
Posaconazole | (n = 69) | (n = 31) |  |  |
 Delayed-release tablet | 27/33 (82%) | 6/33 (18%) | 7.7 (2.6–23.2)a | <0.01 |
 IV | 28/29 (97%) | 1/29 (3%) | 48 (5.9–392.3)a | <0.01 |
 Oral suspension | 14/38 (37% | 24/38 (63%) |  |  |
Voriconazole | (n = 134) | (n = 116) |  |  |
 IV (no. [%]) | 56 (42) | 50 (43) | 1.06 (0.64–1.74) | 0.90 |
 PO (no. [%]) | 78 (58) | 66 (57) |  |  |